News und Analysen

Leading health insurer Cigna Group Inc. (NYSE: CI) was praised for having the foresight to divest its Medicare Advantage (MA) business before rising acute care utilization rates would impact its

AbbVie (NYSE: ABBV) is a high-quality, dividend-growing pharmaceutical company with a robust outlook for growth: now is a good time to load up on shares. Fears of Humira’s patent cliff are

President Trump has endorsed the passage of a tax credit for family caregivers. The tax credit would be given to caregivers who take care of a parent, family member, or a loved one. The AARP

Today’s stock market has brought about a set of distracting indicators and methods to analyze a potential trade—or investment—opportunity, some of which might be accurate in a completely binary

The outlook and technical action suggest Abbott Laboratories (NYSE: ABT) will lead healthcare names like Johnson & Johnson (NYSE: JNJ) higher in 2025. While each produced a solid quarter, Abbott

UnitedHealth Group (NYSE: UNH) stock price is pulling back from highs set last year, presenting a healthy opportunity for investors. Although the outlook for revenue growth has dimmed, the

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotechnology company with a strong track record of success in developing treatments for cystic fibrosis (CF). Vertex is strategically expanding into the

As 2025 kicks off with a volatile start, many investors are likely feeling the pressure of heightened uncertainty. The S&P 500 and other major indices are down year-to-date, led by sharp declines

America’s health insurance industry continues to face scrutiny after it was thrust into the headlines after the murder of UnitedHealth Group Inc. (NYSE: UNH) owned United Healthcare CEO Brian

Capital returns are a driving force for markets and central to the stocks on this list. These stocks pay significant dividends, repurchase shares robustly, or both, and insider buying is strong

Gene-editing kicked off 2024 with a bang in the medical sector but closed the year with a whimper. It started with the FDA approval for the first CRSPR-based gene therapy treatment for sickle cell

The health insurance industry has received a lot of backlash over its managed care practices that bog down providers with pre-authorizations and rampant medical claim denials. The rise in medical

Volume is what drives the entire market, and that is a fact that often gets lost in the sea of indicators, patterns, and trend lines that dominate today’s concept of analysis. However, most

Pharmaceutical giant Pfizer Inc. (NYSE: PFE) stock is trading back down near its pandemic lows. Every time it attempts to climb over the $30 mark, something causes shares to slide right back down